675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Financial Results, Press Release
Material disclosure
GSK Files NDA Resubmission for Tebipenem HBr; $25M Milestone Payment Triggered
Announces Third Quarter 2025 Operating Results and Provides a Business Update
Announces Second Quarter 2025 Operating Results and Provides a Business Update
Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
Announces First Quarter 2025 Operating Results and Provides a Business Update
Q3
Q2
Q1
FY 2024
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Confidential Treatment Order